Evidence map›Paper›PMID 32298331›Full record

ArticlePloS one2020

Expansion and scale-up of HIV care and treatment services in four countries over ten years.

Chloe A Teasdale, Elaine J Abrams, Katharine A Yuengling, Matthew R Lamb, Chunhui Wang, Mirriah Vitale, Mark Hawken, Zenebe Melaku, Harriet Nuwagaba-Biribonwoha, Wafaa M El-Sadr

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chloe A TeasdaleDepartment of Epidemiology & Biostatistics, CUNY Graduate School of Public Health and Health Policy, New York, NY, United States of America.ORCID 0000-0001-9165-8972
Elaine J AbramsICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Katharine A YuenglingICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Matthew R LambICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Chunhui WangICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Mirriah VitaleICAP-Columbia University, Maputo, Mozambique.
Mark HawkenICAP-Columbia University, Nairobi, Kenya.ORCID 0000-0001-9178-6480
Zenebe MelakuICAP-Columbia University, Addis Ababa, Ethiopia.
Harriet Nuwagaba-BiribonwohaDepartment of Epidemiology, Mailman School of Public Health Columbia University, New York, NY, United States of America.
Wafaa M El-SadrICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, United States of America.

Funding

RAPID EXP. OF ART FOR HIV-INFECTED PERSONS IN SELECTED COUNTRIES FOR PEPFARU62PS223540 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EL-SADR, WAFAA M. · 2004 to 2011
$554.7M
TECHNICAL ASSISTANCE IN SUPPORT OF HIV PREVENTION, CARE AND TREATMENT PROGRAMSU2GPS001537 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JUSTMAN, JESSICA · 2009 to 2014
$13.6M
NCHHSTP CDC HHS U2G PS001537NCHHSTP CDC HHS U62 PS223540PEPFAR
6 · The paper itself

Abstract

backgroundScale-up and expansion of antiretroviral therapy (ART) for people living with HIV (PLHIV) have been a global priority for more than 15 years.

methodsWe describe PLHIV at enrollment in care and ART initiation in Ethiopia, Kenya, Mozambique and Tanzania from 2005-2014 and report on enrollment location, CD4 count and loss to follow-up (LTF), death, and combined attrition (LTF and death) pre- and post-ART initiation over time. Pre-ART outcomes were estimated using competing risk and post-ART using Kaplan-Meier estimators; LTF defined as no visit within six months pre-ART and 12 months after ART start.

resultsFrom 2005-2014, 884,328 PLHIV enrolled in care at 350 health facilities, median age was 32.0 years (interquartile range [IQR] 26.0-42.0), and majority were female (66.5%). The proportion of PLHIV enrolled at primary and rural facilities increased from 12.9% and 15.3% in 2005-2006 to 43.5% and 41.7% in 2013-2014 (p<0.0001). Median CD4+ cell count at enrollment increased from 171 cell/mm3 in 2005-2006 (IQR 71-339) to 289 cell/mm3 in 2013-2014 (IQR 133-485) (p<0.0001). A total of 460,758 (57.4%) PLHIV initiated treatment. Cumulative risk of LTF for PLHIV prior to ART initiation 12 months after enrollment was 33.5% (95%CI 33.36-33.58) and 21.98% (95%CI 21.9-22.1) after ART initiation. Pregnant women and the youngest PLHIV group had the highest attrition after ART initiation, at 24 months 40.8% (95%CI 40.1-41.6) of pregnant women and 47.4% (95%CI 46.4-48.4) of PLHIV 15-19 years were not retained. Attrition at 12 months after enrollment among PLHIV regardless of ART status was 38.5% (95%CI 38.4-38.6).

conclusionOver 10 years of HIV scale-up in four sub-Saharan African countries, close to a million PLHIV were enrolled in care increasingly at rural and primary facilities with increasing CD4 count. Loss to follow-up from HIV care remains alarmingly high, particularly among pregnant women and younger PLHIV.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentAdultAnti-HIV AgentsCD4 Lymphocyte CountEthiopiaFemaleHIV InfectionsHumansKaplan-Meier EstimateKenyaLongitudinal StudiesLost to Follow-UpMaleMiddle AgedMozambiqueAnti-HIV Agents

Identifiers

PMID32298331
PMCPMC7162457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.